Free Trial
→ “You all just got a lot richer” (From Brownstone Research) (Ad)
OTCMKTS:BICX

BioCorRx 3/31/2025 Earnings Report

BioCorRx logo
$0.34 +0.03 (+9.68%)
As of 05/30/2025 03:48 PM Eastern
ProfileEarnings History

BioCorRx EPS Results

Actual EPS
-$0.08
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BioCorRx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioCorRx Announcement Details

Quarter
Date
3/31/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

BioCorRx's next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Conference Call Resources

BioCorRx Earnings Headlines

BioCorRx Reports Business Update for the First Quarter of 2025
May 20, 2025 | finance.yahoo.com
BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
March 10, 2025 | finance.yahoo.com
“You all just got a lot richer”
Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crashes. Do you think that’s an accident? When he threatens to “End the Fed” do you think he doesn’t know banking stocks will benefit? What about when he tells his followers, “Now is a good time to buy,” hours before relaxing tariffs and sending the market soaring? Is that an accident? Larry Benedict doesn’t think so. He thinks Trump knows what he’s doing… and believes he’s found the perfect tickers for everyday Americans to take advantage next time he triggers a big move.
June 1, 2025 | Brownstone Research (Ad)
La Rosa Holdings Corp. secures new financing, reshuffles leadership
October 6, 2024 | investing.com
BioCorRx Inc: BioCorRx Reports Business Update for the Second Quarter of 2024
August 16, 2024 | finanznachrichten.de
BioCorRx Reports Business Update for the Second Quarter of 2024
August 15, 2024 | globenewswire.com
See More BioCorRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioCorRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioCorRx and other key companies, straight to your email.

About BioCorRx

BioCorRx (OTCMKTS:BICX), through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

View BioCorRx Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles